Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NTDT

- PMLiVE

CHMP backs oral MS drugs from Sanofi, Biogen Idec

Tecfidera and Aubagio recommended for use in Europe

- PMLiVE

Otsuka’s Pletal has use restricted in Europe

EMA recommends drug only be used in limited group of patients with blood supply disorder

- PMLiVE

Dismay as NICE turns down Afinitor for breast cancer

Patient groups say draft guidance is a major blow to women in England and Wales

Tetra wins Meningitis UK account

Public affairs agency will promote NHS adoption of vaccine 

- PMLiVE

Novartis turns from social networking to apps for trial recruitment

Launches iPhone and Android cancer trial app in the US

- PMLiVE

Black triangle monitoring warning to be used across EU

Use of symbol is part of EMA plans to strengthen pharmacovigilance

- PMLiVE

Incyte says Jakafi patient developed brain virus

Investigation to determine if myelofibrosis drug is linked to PML

Novartis building

Novartis, ThromboGenics’ eye drug Jetrea gets green light in EU

First drug specifically approved for vitreomacular adhesion

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

Vanda withdraws EU application for schizophrenia drug

CHMP had previously refused to back the approval of Fanaptum

- PMLiVE

EMA’s Pharmacovigilance Risk Assessment Committee gains new members

Filip Babylon to represent HCP organisations and Albert van der Zeijden to represent patient organisations

- PMLiVE

AbbVie sues EMA to block Humira data release

Pharma company seeks injunction following FOI requests for raw data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links